Podcast

Differentiators When Choosing Novel Treatment Options for EDS

Launch Date
10/30/2020
Credit Amount
0.00 Expired
Credit Expires
10/31/2022

Faculty

Richard K. Bogan, MD, FCCP, FAASM
Associate Clinical Professor
University of South Carolina Medical School
Columbia, SC
Medical University of South Carolina
Charleston, SC
Principal, Bogan Sleep Consultants, LLC
Columbia, SC
Richard K. Bogan, MD, FCCP, FAASM

Dr. Bogan is the President of Bogan Sleep Consultants, LLC. He is also Associate Clinical Professor at the University of South Carolina School of Medicine and Associate Clinical Professor at the Medical University of South Carolina in Charleston, SC.

Dr. Bogan received his bachelor’s degree in chemistry from Wofford College and his MD degree from the Medical University of South Carolina in Charleston. He served his internship and residency, as well as Chief Medical Resident, at the University of Alabama Hospital and Clinics in Birmingham. Thereafter, he completed a fellowship and assistant professorship in the Pulmonary Division of the Department of Medicine at the University of Alabama School of Medicine. He has been certified by the American boards of Sleep Medicine, Internal Medicine, and Pulmonary Diseases.

Dr. Bogan has served as principal investigator on numerous clinical trials in the past and continues to do so now. He has a variety of publications and research interests that focus on topics such as narcolepsy, insomnia, sleep apnea, shift work sleep disorder, restless legs syndrome/periodic limb movement disorder, chronic fatigue/fibromyalgia, and circadian rhythm abnormality.

Yves Dauvilliers, MD, PhD
Professor of Neurology and Physiology, University of Montpellier
Director, Sleep-Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France
Yves Dauvilliers, MD, PhD

Yves Dauvilliers, MD, PhD, has held the position of Professor of Neurology and Physiology, and Head of the clinical and research activity of the sleep laboratory at the University of Montpellier, France since 2005.  He is also a member of the research group INSERM U1061, and coordinator of the French National Reference Network for Orphan Diseases (Narcolepsy, Hypersomnia, Kleine-Levin Syndrome). He is author or coauthor of more than 370 papers published in international and national peer-reviewed journals, several book chapters. He has also served as editor of three French books related to sleep medicine.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credits

Statement of Need

Reducing excessive daytime sleepiness (EDS) is an important treatment goal for patients with narcolepsy or obstructive sleep apnea (OSA). In order to achieve reduced EDS, cataplexy and sleep paralysis/hypnagogic hallucinations must be controlled to improve disturbed nighttime sleep, which then improves fatigue and brain fog and reduces psychosocial dysfunction, therefore improving quality of life (QoL). The latest efficacy and safety data should be reviewed, and considerations for treatment selection – especially in refractory patients, children, the elderly, or pregnant patients – must be taken into account.

This CMEOCast podcast focuses on developing personalized, effective strategies to reduce EDS in patients with OSA or narcolepsy, including an overview of data on incorporating the use of safer, lower sodium alternatives to mitigate EDS without imposing cardiovascular burden.

Learning Objectives

At the end of this CME/CE activity, participants should be able to apply efficacy and safety data to treatment decisions for EDS in patients with OSA or narcolepsy to improve QoL and functioning.

Financial Support

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Target Audience

Sleep specialists, pulmonologists, neurologists, psychiatrists, primary care physicians, pediatricians, PAs, nurse practitioners, and pharmacists.

Credit Information

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists/Pharmacy Tech (ACPE) 0.5

This application-based activity is approved for 0.5 contact hours (0.05 CEUs) of continuing pharmacy credit.
UAN: 0376-0000-20-155-H01-P

ABIM MOC 0.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Pediatricians (ABP MOC) 1.5

Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 1.5 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Bogan reports that he is a consultant for Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc. He takes part in industry funded research with Avadel/Flamel Ireland LTD; Axsome Therapeutics, Inc.; Balance; Eisai Inc.; Fresca; Jazz Pharmaceuticals, Inc.; and Merck & Co., Inc. He is on the speakers bureau for Jazz Pharmaceuticals, Inc.; and Merck & Co., Inc. He is a shareholder, on the Board of Directors, the Chief Medical Officer, and an employee of SleepMed, Inc. He receives other financial or material support as a member of the Board of Directors for First Community Corporation, SC; and National Sleep Foundation.

Dr. Dauvilliers reports that he receives grants from Jazz Pharmaceuticals, Inc. He receives research support from Bioprojet; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and UCB S.A., Belgium. He is on the advisory committee for Bioprojet; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and UCB S.A., Belgium. He is a consultant for Bioprojet; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; and UCB S.A., Belgium.

Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:

  • Tony Graham, MD (peer reviewer) has no disclosures to report.
  • Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
  • Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
  • Evan Luberger (planning committee) has no disclosures to report.
  • Jan Perez (planning committee) has no disclosures to report.
  • Sharon Tordoff (planning committee) has no disclosures to report

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credits

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

PD-033-103020-43

 

Differentiators When Choosing Novel Treatment Options for EDS
Event Date: 10/30/2020

Related Activities

Sleep Disorders
10/04/2023

Choosing and Optimizing Therapy in Narcolepsy

1.0
Register Learn More
Sleep Disorders
09/01/2023

Recognition of Narcolepsy in Your Patients

0.5
Register Learn More
Sleep Disorders
08/04/2023

Differential Diagnosis for Narcolepsy

0.75
Register Learn More